About us

It is estimated that 38 million people worldwide are currently living with human immunodeficiency virus (HIV). Although the advent of antiretroviral therapy (ART) has significantly improved the life expectancy of people living with HIV (PLWH), ART is not a cure and must be taken for life to prevent the resumption of virus replication and progression to acquired immune deficiency syndrome (AIDS). The emergence of drug resistant HIV strains and increased risk for co-morbidities such as cardiovascular disease, kidney disease, neurocognitive disorders and malignancies among PLWH continue to be a major concern. The goal of our work is to understand the barriers to an effective HIV cure in order to develop innovative therapeutic interventions to limit the need for lifelong ART treatment. This includes the evaluation of therapeutic vaccines, immunotherapy, adjuvants, cytokines and engineered T cells.